- About Us
- Drug Discovery
- Regenerative Medicine
- News & Events
- Contact Us
About Us > Board of Directors
Eli Opper, PhD - Chairman of the Board
Dr. Eli Opper is the former Chief Scientist of the Ministry of Industry, Trade, and Labor in Israel (2002-2002-2011). Prior to his appointment as the Chief Scientist in May 2002, Dr. Opper was a Partner at Giza Venture Capital since 2000. Dr. Opper has held various senior positions at Rafael, Israel's leading defense systems developer including Vice President of Research and Development, Vice President of Advanced Topics, and General Manager of the Electronic Systems Division. Dr. Opper was also the former President of Europe’s Eureka R&D Fund. He has earned his Ph.D. degree in Computer Engineering from the University of Texas, Austin. Dr. Opper also received his B.Sc. and M.Sc. degrees in Electrical Engineering from the Technion.
Yossi Ben-Yossef - Director, Co-Founder
Mr. Ben-Yossef co-founded Kadimastem in 2009, along with Prof. Michel Revel. Prior to Kadimastem, he has been leading investments and taking an active role in successful Biotech/Life Sciences companies in the last 12 years. Among the companies he was involved with are Evogen (TASE: EVGN), Rosetta Genomics (NASDAQ:ROSG), and Biondvax TASE: BNDX.
Prof. Michel Revel, MD, PhD - Director, Co-Founder
Prof. Revel is Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. His research on Interferon, its mechanisms of action and the isolation of the human Interferon-beta gene, have led to the development of Interferon-beta therapy for the treatment of multiple sclerosis, Rebif®, Blockbuster drug marketed worldwide.
In recent years, Prof. Revel's laboratory focused on hESC and succeeded to produce nerve myelinating cells that, when transplanted in myelin-deficient animals, have regenerated the myelin coating. These studies contributed to the development of a suspension culture technology for hESC which can then be used to produce differentiated human cells such as insulin-producing pancreatic beta cells and nerve myelinating cells.
Alongside his research and development activity, Prof. Revel is deeply involved in the ethics of science and biotechnology, and serves as chairman of the Israel National Bioethics Council, and was a member of the International Bioethics Committee of UNESCO.
Prof. Revel was the recipient of the Israel Prize for medical research, the EMET Prize for biotechnology, and is a member of the Israel Academy of Science and Humanities. He has been a member of Israel's National Committee for Biotechnology, serving for three years as its chairman.
Julien Ruggeri - Director
Mr. Ruggieri serves as Director of Monroe SA, a Luxembourg based investment company, wholly owned by the Batipart group (http://www.batipart.com). Before joining the Batipart Group, Mr. Ruggieri worked at Morgan Stanley Real Estate Funds (MSREF) in New York , after having worked for an American subsidiary of the Arcelor Mittal. He serves as the Chairman of the Board at Maelys SA, Fond Light Ltd. and Vice Chairman at Jardiland SA. He serves as a Member of Board of Directors at Proméo SA, Delta Car Trade SA and Onomo International SAS. He serves as a Representative Member of Supervisory Board at Korian SA. Mr. Ruggieri is a graduate of the European Business School and holds a DESS post-graduate degree in Audit from IAE, Aix-en-Provence and an MBA from the Johnson School at Cornell University.
Eynat Tsafrir - Director
Ms. Tsafrir has more than 20 years of experience in the banking and financial field, serving in various roles in Bank Discount and Bank Leumi, two of Israel's leading banks. As part of her responsibilities as Business Development Manager at Bank Discount, Ms. Tsafrir led the bank's capital markets reorganization, and established several new departments in the areas of derivatives. In Bank Leumi, Ms. Tsafrir served in several positions, including establishing and managing the capital markets division, Business Manager of the Commercial Banking Division and Economist in the bank's Economics Division. In parallel to her work as an economist in the Economics Division of Bank Leumi, Ms. Tsafrir finished her MA in Economics and worked in various academic institutions as a lecturer, research assistant and teaching assistant. Since 2010, Ms. Tsafrir has been serving as an independent financial consultant, as well as an External Director at Altshuler Shacham Investment House. She also served as a director for Afcon Technologies Ltd. until 2012. Ms. Tsafrir holds a B.A and M.A in Economics from the Tel Aviv University.
Rami Epstein, Adv. - Director
Mr. Epstein is the owner of R. Epstein & Co.; Law Offices, a private practice with emphasis on Commercial and Corporate Law, International Trade Law, Banking, Energy, Hi-tech and Biotech. In addition, Mr. Epstein is the founder of Biondvax Pharmaceuticals Ltd. (TASE:BNDX) and IDgene Pharamaceuticals Ltd.. In addition, Mr. Epstein is a certified mediator, a member of the Legislative Committee for Science and Technology of the Israeli Bar, and Vice President of the Legislative Committee for Environment and Cleantech of the Israeli Bar. Mr. Epstein holds an LL.B from the Hebrew University of Jerusalem, and a LL.M from King's College, University of London.
Adina Makover, Ph.D - External Director
Dr. Makover has more than 20 years of experience in various fields of biotech and medical devices including drug development, diagnostics, tissue engineering, as well as venture capital investments. Among her roles, she served as the CEO of a start-up company engaged in proof of concept of tissue banking and tissue culture for tissue engineering. In addition, Dr. Makover serves as a Director at the boards of Evogene (TASE:EVGN), Perfaction Technologies, Earlysense, Genegrafts, Spine21, and as an Observer at Argo Medical. Dr. Makover has earned her joint Ph.D from Columbia University and the Weizmann Institute, and holds an MBA from Bar Ilan University.
Avi Bzura - External Director
Mr. Bzura has more than 20 years of experience in the financial industry. Between 2011-2013, Mr. Bzura was CEO of BDRM Finance, a private equity firm. Prior to his role at BDRM, from 1990-2011, Mr. Bzura served in various senior positions in Bank Hapoalim and Bank of Jerusalem, where he was CEO and Chariman of the Board from 2007-2011. Mr. Bzura holds a B.A in Economics from Tel Aviv Univesity, and an MBA from Bar Ilan University.
Avi Meizler - Director
Mr. Meizler is a leading figure in the pharmaceutical industry in South America in general, and in Brazil in particular. With a group of partners, Meizler recently invested in Nasvax Ltd. UCB is a partner in his company, Meizler UCB Biopharma. Meizler is also the joint owner of Advantech, which engages in the development and commercialization of biological drugs. Mr. Meizler is one of the largest private investors in Brainsway, whose products he distributes in Brazil. In addition, Mr. Meizler has invested in Therapix Bioscience and the life sciences company Nirolin.
Ofer Haviv - Observer
Mr. Haviv is the CEO of Evogene (TASE:EVGN). Prior to being named CEO of Evogene in late 2004, MR. Haviv held the positions of company COO and CFO from 2002 to 2004 and was involved in Evogene's spin-off from Compugen. Prior to the spin-off, he held the position of Director of Finance and Treasurer of Compugen for four years, during which time the company completed two private placements and an IPO on NASDAQ. Earlier, Mr. Haviv was the CFO of Klei Zemmer. He was also an auditor with a leading accounting firm belonging to a network of the "Big Five".
Amir Naiberg - Observer
Mr. Naiberg is the CEO of Yeda Research and Development Company Ltd., the Technology Transfer Company of the Weizmann Institute of Science. Yeda markets and commercializes intellectual property created at the Weizmann Institute laboratories.
Olivier Samuel - Observer
Mr Samuel serves as CEO since 1997 of Adomasante who recently acquired Darmian, another company specialized in medical services for the elderly populations in France. He also leads a consulting activity in geriatric care management since 2001 for leading operators and brands in medical hardware (Hartmann), nursing homes (Korian), Telco operators (Orange Healthcare) and care insurance (Mederic Malakoff). Mr Samuel is a graduate of the EM Lyon Business School and from Lille’s Health Engineers school.
Yigal Fatran - Director
Mr Fatran has over 35 years of financial and industrial experience. Mr. Fatran's resume includes senior positions at Israeli corporations in the biotech hi-tech industry and he serves as a member of the boards of directors of several Israeli companies (both public and private), including Medivie Therapeutics, Electronics Line Ltd. And Jobookit Holdings Ltd..Mr. Fatran holds B.Sc degrees in Computer Science and Economics, both from Bar Ilan University.